Supernus Pharm (SUPN)

$37.74 -0.13 (-0.34%)
Market Cap 2.09B
Revenue (ttm) 607.52M
Net Income (ttm) 1.32M
EPS (ttm) N/A
PE Ratio 28.25
Forward PE 26.77
Profit Margin 0.22%
Debt to Equity Ratio 0.00
Volume 199,700
Avg Vol 387,082
Day's Range N/A - N/A
Shares Out 55.22M
Stochastic %K 95%
Beta 0.90
Analysts Strong Sell
Price Target $39.25

Latest News on SUPN

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Dec 16, 2024, 4:30 PM EST - 4 weeks ago

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 5:00 PM EST - 7 weeks ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 2 months ago

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12, 2024, 11:57 AM EST - 2 months ago

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 10:51 PM EST - 2 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Oct 31, 2024, 4:10 PM EDT - 2 months ago

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Oct 21, 2024, 4:25 PM EDT - 3 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Oct 17, 2024, 4:05 PM EDT - 3 months ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Oct 10, 2024, 5:12 PM EDT - 3 months ago

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Sep 24, 2024, 7:30 AM EDT - 4 months ago

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 19, 2024, 4:30 PM EDT - 4 months ago

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 11, 2024, 11:25 PM EDT - 4 months ago

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Sep 11, 2024, 2:38 PM EDT - 4 months ago

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 28, 2024, 4:15 PM EDT - 5 months ago

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Aug 19, 2024, 7:00 AM EDT - 5 months ago

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:05 PM EDT - 5 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript

Supernus Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 4:06 PM EDT - 5 months ago

Supernus Announces Second Quarter 2024 Financial Results

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Aug 1, 2024, 4:30 PM EDT - 6 months ago

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Jul 23, 2024, 4:13 PM EDT - 6 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 4:25 PM EDT - 8 months ago

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

May 23, 2024, 4:05 PM EDT - 8 months ago

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

May 9, 2024, 4:05 PM EDT - 9 months ago

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript

May 8, 2024, 8:28 PM EDT - 9 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript

Supernus Announces First Quarter 2024 Financial Results

May 8, 2024, 4:05 PM EDT - 9 months ago

Supernus Announces First Quarter 2024 Financial Results

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

May 7, 2024, 10:00 AM EDT - 9 months ago

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

May 2, 2024, 11:00 AM EDT - 9 months ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

May 1, 2024, 8:00 AM EDT - 9 months ago

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Apr 29, 2024, 7:20 PM EDT - 9 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Apr 24, 2024, 4:05 PM EDT - 9 months ago

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Supernus Provides Regulatory Update for SPN-830

Apr 8, 2024, 8:00 AM EDT - 10 months ago

Supernus Provides Regulatory Update for SPN-830

Supernus to Participate in Two Upcoming Investor Conferences

Mar 6, 2024, 4:30 PM EST - 11 months ago

Supernus to Participate in Two Upcoming Investor Conferences

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 4:30 PM EST - 11 months ago

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 9:41 PM EST - 11 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 11 months ago

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024

Feb 13, 2024, 4:05 PM EST - 1 year ago

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

Feb 5, 2024, 8:30 AM EST - 1 year ago

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

Dec 19, 2023, 7:30 AM EST - 1 year ago

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity

Nov 10, 2023, 2:22 PM EST - 1 year ago

Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:38 PM EST - 1 year ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Call Transcript

Supernus Announces Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Supernus Announces Third Quarter 2023 Financial Results

Supernus to Participate in the Jefferies London Healthcare Conference

Nov 7, 2023, 4:30 PM EST - 1 year ago

Supernus to Participate in the Jefferies London Healthcare Conference

Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023

Oct 25, 2023, 4:15 PM EDT - 1 year ago

Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

Oct 16, 2023, 5:34 PM EDT - 1 year ago

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City

Sep 27, 2023, 4:15 PM EDT - 1 year ago

Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City

Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms

Sep 9, 2023, 8:00 PM EDT - 1 year ago

Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms

Supernus to Participate in the Wells Fargo Healthcare Conference

Aug 31, 2023, 5:30 PM EDT - 1 year ago

Supernus to Participate in the Wells Fargo Healthcare Conference

Bethany L. Sensenig Joins Supernus' Board of Directors

Aug 21, 2023, 9:00 AM EDT - 1 year ago

Bethany L. Sensenig Joins Supernus' Board of Directors

Supernus Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 4:17 PM EDT - 1 year ago

Supernus Announces Second Quarter 2023 Financial Results